Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive...
20 KB (1,623 words) - 12:42, 5 August 2024
resulted in what is now known as the compound ponatinib. X-ray crystallographic analysis of ponatinib and T315I Bcr-Abl mutated kinase display that the...
56 KB (6,473 words) - 03:56, 5 July 2024
ARIAD Pharmaceuticals (section Ponatinib (Iclusig))
emergency-access program for Ponatinib, which provided drugs to patients in need during this six-week period. Ponatinib remained on the market in all...
16 KB (1,353 words) - 15:19, 7 August 2024
T315I, as well as all other known mutations of the oncoprotein. The drug, ponatinib, gained FDA approval in December 2012 for treatment of patients with resistant...
34 KB (3,877 words) - 01:25, 22 July 2024
(Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib). In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280...
11 KB (763 words) - 16:06, 3 June 2024
Angelica; Zhang, Qinkun; Prabhu, Sumanth D.; Lal, Hind (2023-02-03). "Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation"...
14 KB (1,442 words) - 03:32, 9 August 2024
(Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib (Scemblix) Bortezomib (Velcade) is an apoptosis-inducing...
20 KB (2,234 words) - 01:21, 22 July 2024
Mitoxantrone Nelarabine Nilotinib Oblimersen Pegaspargase Pentostatin Ponatinib Prednisone Rituximab Tretinoin Vincristine "Drugs Approved for Leukemia...
1 KB (70 words) - 18:51, 14 November 2023
The molecular formula C29H27F3N6O may refer to: Olverembatinib Ponatinib This set index page lists chemical structure articles associated with the same...
522 bytes (44 words) - 03:29, 20 December 2023
inhibitors to treat CML are imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Gastrointestinal stromal tumors (GIST) are known to withstand cancer...
43 KB (5,251 words) - 10:44, 24 June 2024
cabozantinib cancer lapatinib cancer lenvatinib cancer pazopanib cancer ponatinib cancer ramucirumab cancer ranibizumab AMD regorafenib cancer sorafenib...
14 KB (1,671 words) - 12:47, 23 April 2024
Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase Baricitinib Fedratinib...
12 KB (760 words) - 03:40, 23 July 2024
(Allergan) pomalidomide (USAN) Pombiliti pomisartan (INN) ponalrestat (INN) ponatinib (INN) ponezumab (USAN) ponfibrate (INN) Ponstel porfimer sodium (INN)...
8 KB (416 words) - 22:16, 23 March 2024
Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase Baricitinib Fedratinib...
12 KB (758 words) - 23:46, 14 March 2024
mutation that affects most ATP-competitive active site inhibitors, except ponatinib. Common side effects of Asciminib are symptoms of a cold, muscle pain...
17 KB (1,263 words) - 09:31, 30 July 2024
(uncommon) and reversible posterior leucoencephalopathy syndrome (rare). Ponatinib PO Multikinase inhibitor (BEGFR, PDGFR, FGFR, EPH receptors and SRC families...
52 KB (708 words) - 00:21, 11 April 2024
Imatinib L01EA02 Dasatinib L01EA03 Nilotinib L01EA04 Bosutinib L01EA05 Ponatinib L01EA06 Asciminib L01EB01 Gefitinib L01EB02 Erlotinib L01EB03 Afatinib...
12 KB (877 words) - 15:36, 25 January 2024
tract infection None - +/- ++ N/A B 17 December 2004 31 January 2006 N/A Ponatinib ARIAD Pharmaceuticals Bcr-Abl, BEGFR, PDGFR, FGFR, EPH, SRC, c-KIT, RET...
23 KB (742 words) - 04:57, 30 December 2023
transplantion in order to improve survival. The tyrosine kinase inhibitor Ponatinib has been used as mono-therapy and subsequently used in combination with...
44 KB (5,003 words) - 08:59, 15 July 2024
former two mutations; a later generation tyrosine kinase inhibitors, ponatinib, alone or combined with bone marrow transplantation, may be useful for...
16 KB (1,795 words) - 11:37, 25 August 2023
former two mutations; a later generation tyrosine kinase inhibitors, ponatinib, alone or combined with bone marrow transplantation, may be useful for...
32 KB (3,618 words) - 03:33, 3 December 2023
disrupt oncogene addiction include imatinib, nilotinib, dasatinib, and ponatinib, among others. While initial treatment may have striking, positive results...
4 KB (452 words) - 07:30, 28 February 2023
transplantion has been used to improve survival. The tyrosine kinase inhibitor Ponatinib has been used as mono-therapy and subsequently used in combination with...
48 KB (5,760 words) - 23:15, 2 December 2023
Asp850Val mutant. Two other tyrosine kinase inhibitors, dasatinib and ponatinib, do inhibit the p.Asp850Val mutant's tyrosine kinase activity. Limited...
31 KB (3,744 words) - 05:37, 3 August 2024
forms of BCR-ABL. These include dasatinib, nilotinib, bosutinib, and ponatinib. Cancer pharmacogenomics has also contributed to the understanding of...
36 KB (4,062 words) - 06:00, 17 June 2024